Pacific Edge Limited is a cancer diagnostics company based in Dunedin, New Zealand, specializing in the research, development, and commercialization of diagnostic and prognostic tools for cancer detection and management. The company operates primarily in two segments: Commercial and Research. Its flagship product, Cxbladder, is a genomic urine test designed for the detection and management of bladder cancer. Additionally, Pacific Edge is developing Cxbladder Resolve, aimed at identifying high-grade or late-stage bladder cancer, and Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients with stage II or III colorectal cancers, which are currently undergoing clinical trials. The company is also exploring potential products for gastric, melanoma, and endometrial cancers that are in pre-clinical stages. Founded in 2001, Pacific Edge strives to create clinically impactful cancer diagnostic tests by leveraging proprietary genetic databases to identify relevant biomarkers.